Samtidigt bliver EMEA nødt til fortsat at koncentrere sig om at forvalte sin kernevirksomhed, som er at vurdere nye ansøgninger og overvåge et stadig større antal godkendte lægemidler.
As the Community body responsible for the evaluation and supervision of medicines, the EMEA has a clear role to play in this and has seen a number of new tasks added to its existing responsibilities by the EU institutions and Member States.